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Background. Influenza A viruses generate an extreme genetic diversity through point mutation and gene segment exchange,
resulting in many new strains that emerge from the animal reservoirs, among which was the recent highly pathogenic H5N1
virus. This genetic diversity also endows these viruses with a dynamic adaptability to their habitats, one result being the rapid
selection of genomic variants that resist the immune responses of infected hosts. With the possibility of an influenza A
pandemic, a critical need is a vaccine that will recognize and protect against any influenza A pathogen. One feasible approach
is a vaccine containing conserved immunogenic protein sequences that represent the genotypic diversity of all current and
future avian and human influenza viruses as an alternative to current vaccines that address only the known circulating virus
strains. Methodology/Principal Findings. Methodologies for large-scale analysis of the evolutionary variability of the
influenza A virus proteins recorded in public databases were developed and used to elucidate the amino acid sequence
diversity and conservation of 36,343 sequences of the 11 viral proteins of the recorded virus isolates of the past 30 years.
Technologies were also applied to identify the conserved amino acid sequences from isolates of the past decade, and to
evaluate the predicted human lymphocyte antigen (HLA) supertype-restricted class I and II T-cell epitopes of the conserved
sequences. Fifty-five (55) sequences of 9 or more amino acids of the polymerases (PB2, PB1, and PA), nucleoprotein (NP), and
matrix 1 (M1) proteins were completely conserved in at least 80%, many in 95 to 100%, of the avian and human influenza A
virus isolates despite the marked evolutionary variability of the viruses. Almost all (50) of these conserved sequences
contained putative supertype HLA class I or class II epitopes as predicted by 4 peptide-HLA binding algorithms. Additionally,
data of the Immune Epitope Database (IEDB) include 29 experimentally identified HLA class I and II T-cell epitopes present in
14 of the conserved sequences. Conclusions/Significance. This study of all reported influenza A virus protein sequences,
avian and human, has identified 55 highly conserved sequences, most of which are predicted to have immune relevance as T-
cell epitopes. This is a necessary first step in the design and analysis of a polyepitope, pan-influenza A vaccine. In addition to
the application described herein, these technologies can be applied to other pathogens and to other therapeutic modalities
designed to attack DNA, RNA, or protein sequences critical to pathogen function.
Citation: Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, et al (2007) Evolutionarily Conserved Protein Sequences of Influenza A Viruses, Avian
and Human, as Vaccine Targets. PLoS ONE 2(11): e1190. doi:10.1371/journal.pone.0001190
INTRODUCTION
One of the most important threats to human health is infection by
avian influenza A viruses [1-3]. While global influenza pandemics
have occurred only a few times in the past century, the H1N1
pandemic of 1918–1919 caused 20–50 million deaths and was one
of the most serious disease outbreaks in recorded history. The
recent evolution of the highly lethal avian H5N1 virus, while not
transmissible in humans, has emphasized the continued threat of
influenza viruses on a global scale. It is widely predicted, given the
increased human population and density, that a new pandemic on
the scale of the H1N1 infection would have a devastating effect
world-wide.
The two currently approved vaccines against influenza viruses
are designed specifically to mimic the most recently recognized
circulating forms listed in the 2006–2007 influenza prevention and
control recommendations (http://www.cdc.gov/mmwr/preview/
mmwrhtml/rr5510a1.htm). Both vaccines contain three recently
isolated human strains and are subject to possible annual revision
of their virus composition. The rapid mutation of the viral HA and
NA proteins facilitates the selective replication of new virus strains
not subject to immunity based on previous vaccination and is
a serious obstacle to the effectiveness of these vaccines [4–5].
Alternative vaccine strategies that overcome the problem of rapid
viral mutation, can be applied to global populations, and provide
for easy production are suggested goals [6–8].
The design of a vaccine that guarantees antibody-mediated
immunity to new influenza viruses is not currently feasible because
the structural determinants of B-cell immunity are highly complex
and there is no effective means for predicting the antibody epitope
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contrast, is based upon the binding of short sequences of antigen
proteins, termed T-cell epitopes, to specialized cellular proteins,
known as human leukocyte antigens (HLAs), class I (HLA I) and
class II (HLA II), that facilitate the presentation of the epitopes to
T-cells of the immune system [9–14]. The chemical and structural
determinants of HLA-peptide binding have been defined for
a number of HLA alleles [15–19]. Of particular relevance for
vaccine design are supertype groupings of similar HLA alleles that
display overlapping peptide-binding capacities. The supertypes
cover a large fraction of the HLA diversity in the human
population and antigen epitopes that bind to the supertypes are
considered prime candidates for vaccine formulations [20–24].
Supertype-binding motifs and quantitative matrices have been
incorporated into several computational prediction algorithms and
it is now possible to identify, in silico, candidate HLA-restricted T-
cell epitopes of protein sequences, allowing large-scale analysis of
potential vaccine targets [24–27]. Moreover, increasing attention
is being given to T-cell-based vaccines because they can be
designed as genetic formulations to include selected regions of the
viral antigens [28–31], and have the many other desirable
properties associated with DNA vaccines in general. Studies have
demonstrated that epitope-specific T cell responses elicited by
immunization with DNA or peptide, and adoptive transfer of
epitope-specific T cell clones, could mediate protective immunity,
in some cases with single CTL epitopes, against various pathogens
in murine experimental models [32–42]. Additionally, recent
studies have shown that immunization of HLA-A2 transgenic mice
against single HLA-A2-restricted T-cell epitopes conferred pro-
tection against lethal infection with influenza A virus, vaccinia
virus, or LCMV [43–45]. Human clinical trials with epitope-based
DNA vaccines against HIV [46] and malaria [47] were found to
be safe and immunogenic for effector T-cell immune responses but
in these first generation studies, failed to achieve the desired
clinical goals in the vaccination of healthy volunteers.
Cellular immune responses are recognized to play a role in
influenza immunity (for reviews see [48–51] and the application of
T-cell epitopes has been extensively studied as an alternative to
vaccines designed for humoral immunity [52–62]. Mouse
immunization with DNA encoding NP elicited CTL, IFN-c and
IL-2 responses, with cross-strain protection against virus challenge,
and evidence from adoptive transfer, indicated that both types of
T cells act as effectors in protective immunity [54–55]. Similarly,
DNA immunization with H1N1 NP or H5N1 NP or M proteins
was found to protect mice against lethal challenge [56–58].
However, some influenza vaccine formulations were not successful
[59–62] and there remain multiple issues for the development of
a human T-cell epitope-based vaccines, including epitope
selection, delivery systems, epitope processing and presentation,
and undoubtedly others.
This study was focused on the large-scale analysis of all
influenza A virus protein sequence data of the past 30 years that is
recorded in public databases. Information entropy and consensus
sequence methodologies were combined to identify sequences of 9
amino acids or longer with a history of complete conservation in
80% or more of both avian and human virus strains. These
conserved sequences were further analyzed to identify targets for
candidate epitope-based T-cell vaccine formulations against all
current and possibly future influenza A pathogens of avian or
human origin.
METHODS
Methodology overview
A general overview of the methodology is depicted in Figure 1.
The details and rationale for the systematic approach adopted by
this study have been previously published [63]. The primary goal
was to identify viral protein sequences that have been conserved
over long periods of time, and to select those sequences that have
the highest potential for HLA-restricted immunogenicity in a broad
spectrum of the human population. The process includes three
major steps: i) extraction of all influenza A protein sequence data,
processing and definition of data sets comprising relevant human
and avian virus groups; ii) entropy analysis of sequence variability
and identification of conserved peptide sequences of 9 amino acids
or longer; and iii) prediction of supertype-restricted, HLA-binding
sequences. Two complementary methods for the identification of
conserved sequences were applied: a statistical entropy-based
method thattakesintoaccount thecombinatorial diversityofpeptide
epitopes and was used to elucidate the variability for different
influenza subtypes, and a consensus method, which is robust against
sampling biases (such as the predominance of certain influenza
subtypes in the dataset), to confirm the conserved sequences. The
conserved sequences were then submitted to several epitope
prediction programs, whose results are combined. Sequences
predicted, and in some cases demonstrated, to contain epitopes to
Figure 1. An overview of the methodology of this study.
doi:10.1371/journal.pone.0001190.g001
Influenza A Conservation
PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1190several HLA supertypes are proposed as vaccine epitope candidates
because of their wide human population coverage.
Influenza A virus sequence data collection and
processing
A dataset of influenza A protein sequences annotated with isolate
name, country and year of isolation, host organism, subtype, and
protein name, was derived from all available sequences (as of
September 2006) from the NCBI GenBank and GenPept
databases, including entries mirrored from the UniProt database.
Collection and cleaning of a total of 85,873 records was performed
the Aggregator of Biological Knowledge (ABK) [64], which
applied structural and semantic rules to automate the aggregation
and annotation task. The final set of 36,343 protein sequences was
manually verified by two independent curators. Most human
influenza subtypes were represented by more than 100 sequences
of each viral protein, the count varying depending on the protein.
The H1N2 subtype had a lower number of sequences (ranging
from 22 to 66) because of its recent emergence [65]. Separate
multiple sequence alignments of the 11 proteins were carried out
with MUSCLE 3.6 [66]. Because of the great variability exhibited
by the HA and NA proteins, separate alignments were obtained
for each subtype (16 subtypes for HA and 9 for NA). The subtype
alignments were subsequently merged using the MUSCLE tool, to
obtain the final HA and NA alignments. The introduction of gaps
in the resulting alignments was minimized by merging sequences
based on sequence similarity between subtypes, as reported in
phylogenetic studies [5,67]. The in-house developed Antigenic
Variability Analyser tool (AVANA) was subsequently used to
extract alignments of several subsets of the collected sequences,
based on annotation values, such as viral subtype, host, and year of
isolation.
Information entropy analysis
The diversity of the influenza A virus proteome was studied by
creating subsets of the influenza A protein sequence alignments,
comprising (1) avian sequences, subdivided into 3 decades (1977–
1986, 1987–1996, and 1997–2006); (2) H5N1 viruses, subdivided
into avian and human isolates; (3) circulating human subtypes,
namely H1N1, H3N2, and H1N2. Assuming that each sequence
represents an independent isolate, the information entropy method-
ology [68] was used to measure the variability of influenza A virus
proteomes in the context of overlapping nine-amino acid peptides
spanning thelength ofeachinfluenzaA protein.The rationale ofthis
selection was the length of peptides that are bound by HLA
molecules for presentation to T-cell receptors, typically from 8–20
amino acids, with nine amino acids being the predominant length of
class I peptides and the core of class II peptides [69]. Applying
Shannon’s formula [68], the nonamer peptide entropy H(x) at any
given position x in the alignment is computed by
H(x)~{
X n(x)
i~1
p(i,x)log 2 p(i,x)
where p(i,x) is the probability of a particular nonamer variant i being
centered at position x. The entropyvalue increases with n(x), the total
number of variants observed at position x; it is also sensitive to the
relative frequency of the variants, such that it decreases when one
variant is clearly dominant (i.e. the position is conserved). Only
sequences that contain a valid amino acid at position x were used for
the entropy computation, and alignment gaps were ignored.
Although gaps tend to occur in high-diversity regions, proteins that
have a high fraction of gaps have reduced statistical support, yielding
an artificially low entropy value; for this reason, positions where
more than 50% of sequences contained a gap were discarded.
Because of the statistical nature of the entropy measure, both
complete protein sequences and shorter fragments were used in this
computation.
In theory, nonamer entropy values can range from 0,
a completely conserved nonamer sequence in all proteins
analyzed, to 2
9; in practice, however, the upper bound is very
much lower for alignments of closely related sequences. For finite-
size sets of sequences, entropy computations are affected by the
sequence count in the alignment. The effects of alignment size bias
are especially noticeable for alignments containing fewer than
about 100 sequences, and must be accounted for when making
direct comparisons between sequence alignments of different sizes.
It has been shown that, for an alignment of N sequences,
alignment size bias is proportional to 1/N [70]. This relationship
allows a correction for size bias by applying to each alignment
a statistical adjustment that estimates entropy values for an
infinitely-sized alignment with analogous variant distribution. To
obtain such estimate, the alignment was repeatedly randomly
sampled to create smaller alignments of varying size, whose
entropy was measured. At each alignment position, the entropy of
these subset alignments of size N was plotted against 1/N, using
a linear regression to extrapolate the entropy estimate for NR‘.
The regression’s coefficient of determination (r
2) was used as
a goodness-of-fit of the resulting estimate, confirming the validity
of our method (r
2.0.9 in most cases). In this study, size bias
correction was applied to all entropy calculations, so that
alignment sequence counts could be ignored in comparisons. All
entropy values reported are therefore infinite-size set estimates,
rather than the values directly computed from the alignments.
Conserved influenza A virus sequences
Collected and cleaned influenza A virus records were grouped
based on (a) subtype: the circulating human subtypes (H1N1,
H3N2, H1N2), H5N1, and other subtypes in avian reservoir; (b)
host: human and avian; and (c) year of isolation. The method gave
equal weight to all groups and obviated the problem of particular
groups being over-represented (such as human H3N2). Six
subgroups were derived: (1) human H1N1, (2) human H3N2, (3)
human H1N2, (4) human H5N1, (5) avian H5N1, and (6) other
avian subtypes. The eleven influenza A proteins of each subgroups
were individually aligned using MUSCLE 3.6 [66]. The AVANA
tool was used to select nonamers with conservation of $80% in
each alignment. The minimum length of a conserved sequence
was nine amino acids and conserved contiguous nonamers were
joined as a single sequence. A consensus sequence (the most
frequent sequence) for each conserved sequence in the alignments
was generated for each of the 6 subgroups. Corresponding
consensus sequences of the subgroups were then aligned and those
sequences that were identical in each of the six subgroups and
present in at least 80% of all recorded viruses were selected as the
highly conserved sequences.
HLA supertype-restricted T-cell epitopes
The in silico prediction of HLA supertype-restricted HLA class I
and class II T-cell epitope sequences in the conserved regions was
performed through four computational systems: NetCTL MUL-
TIPRED, ARB, and TEPITOPE. The NetCTL 1.2 algorithm
[25] (http://www.cbs.dtu.dk/services/NetCTL/) predicts pep-
tides restricted to 12 HLA class I supertypes (A1, A2, A3, A24,
A26, B7, B8, B27, B39, B44, B58 and B62), integrated with
Influenza A Conservation
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transport efficiency by the transporter associated with antigen
processing (TAP) molecules. HLA binding and proteasomal
cleavage predictions are performed by an artificial neural networks
(ANN) method and TAP transport efficiency is predicted using
a weight matrix method. The parameters used for NetCTL
prediction were: 0.15 weight on C terminal cleavage (default), 0.05
weight on TAP transport efficiency (default), and 0.5 threshold for
HLA supertype binding.
The Average Relative Binding (ARB) matrix binding prediction
method (http://epitope.liai.org:8080/matrix/matrix_prediction.
jsp) [27] is allele specific and estimates a matrix of coefficients
based upon the association of each of the 20 amino acids at each
possible position along the peptide sequence. In this study the data
were selected for representative alleles within studied supertypes
and predictions are shown for 8 HLA class I alleles of the
supertypes A1 (A*0101), A2 (A*0201), A3 (A*0301), A24 (A*2402),
A26 (A*2601), B7 (B*0702), and B44 (B*4402, B*4403).
MULTIPRED (http://research.i2r.a-star.edu.sg/multipred/)
[26] predicts peptides that bind to HLA class I supertypes A2
(A*0201, *0202, *0203, *0204, *0205, *0206, *0207 and *0209)
and A3 (A*0301, *0302, *1101, *1102, *3101, *3301 and
*6801)and class II HLA-DR supertype (DRB1*0101, *0401,
*1501, *0701, *0901, *1302 and DRB5*0101). Hidden Markov
model (HMM) and ANN methods are the predictive engines with
sum thresholds of: A2, 31.33 (ANN; SN=0.80 and SP=0.83) and
47.08 (HMM; SN=0.80 and SP=0.78); A3, 24.53 (ANN;
SN=0.90 and SP=0.95) and 37.58 (HMM; SN=0.80 and
SP=0.87); and DR, 23.42 (ANN; SN=0.90 and SP=0.92) and
51.08 (HMM; SN=0.90 and SP=1.00). TEPITOPE predicts 25
HLA class II (DR) alleles are HLA allele-specific; however,
sequences predicted to bind to $5 alleles were considered
supertypic.
The TEPITOPE software [24] (2000 beta version; obtained by
the courtesy of J. Hammer) utilizes quantitative matrix-based
motifs, obtained from experimental scanning of the binding of P1-
anchored designer peptides to soluble HLA-DR molecules in in-
vitro competition assays, to predict peptides binding to 25 common
HLA-DR alleles (DRB1*0101, *0102, *0301, *0401, *0402,
*0404, *0405, *0410, *0421, *0701, *0801, *0802, *0804, *0806,
*1101, *1104, *1106, *1107, *1305, *1307, *1311, *1321, *1501,
*1502 and DRB5*0101). The parameters for TEPITOPE
predictions were: 5% quantitative threshold and putative determi-
nants with a 10-fold inhibitory residue excluded. Predictions were
performed for all 25 HLA-DR alleles and nonamer core peptides
predicted to bind .5 HLA-DR alleles were selected as supertype-
restricted.
Experimentally identified influenza A T-cell epitopes
T-cell epitope sequences within the conserved sequences were
identified by matching the highly conserved sequences and the
curated influenza epitope sequences obtained from the Immune
Epitope Database and Analysis Resource (www.immuneepitope.
org/) [71,72]. These epitope sequences data were derived from
reported HLA binding assays (IC50#500 nM) or T-cell assays
that included
51Cr release, HLA tetramer staining, and ELISPOT
assays. Only epitope data from unique sequences and containing
HLA restriction information were included.
RESULTS
Avian and human influenza A virus isolates
The collected and cleaned influenza A virus protein sequences
were catalogued in two groups. The recently circulating (1997–
2006) influenza A viruses, both avian and human comprising
25,812 sequences of the 11 influenza proteins, both full- and
partial-length, from human H1N1 (2,466 sequences), H3N2
(12,199), H1N2 (405), H5N1 (1,055), avian H5N1 (4,361), and
all other avian subtypes except H5N1 (5,326) (Table 1). There
were over 100 sequences of each protein of every virus with
exceptions for the most recent human viruses, H1N2 and H5N1,
and the PB1-F2 protein. The second group comprised an
additional 10,531 sequences of human H1N1 and H3N2 isolated
prior to 1997, and all avian viruses isolated from 1977 to 1986,
and 1987 to 1996 (Table 2). The H1N2 sequences before 1997
were excluded because the number of sequences that were
available for analysis was insufficient.
Diversity of influenza A virus proteins
The diversity in the protein sequences of influenza A viruses was
examined by application of the information entropy methodology
to each 9 amino acid sequence of the viral proteins. Data of the
Table 1. Influenza types A virus protein sequences from the past decade (1997–2006).
..................................................................................................................................................
Protein Human H1N1 Human H3N2 Human H1N2 Human H5N1 Avian H5N1
a Other Avian
b Total
PB2 189 970 33 97 404 401 2,094
PB1 202 984 32 101 400 399 2,118
PB1-F2 183 955 22 47 10 74 1,291
PA 190 970 29 102 402 390 2,083
HA 517 2,032 66 106 657 976 4,354
NP 191 1,012 39 114 420 518 2,294
NA 230 1,245 49 112 577 570 2,783
M1 192 1,024 40 105 458 617 2,436
M2 192 1,045 31 95 289 335 1,987
NS1 190 984 36 95 456 662 2,423
NS2 190 978 28 81 288 384 1,949
Total 2,466 12,199 405 1,055 4,361 5,326 25,812
aAll available sequences in the database, mainly from the past decade (1997–2006).
bOther avian subtypes except H5N1, from 1997 to 2006.
doi:10.1371/journal.pone.0001190.t001
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sequences (1977–1986, 2,543 sequences; 1987–1996, 1,711;
1997–2006, 5,326 (Table 1 and 2, Figure 2). The gross patterns
of protein variability of the avian viruses from each of the past 3
decades were very similar in the context of the relative diversity of
the proteins. The viral surface glycoproteins, HA and NA, showed
extreme sequence diversity, illustrative of the reassortment of the
genome segments among the many subtypes of the avian group A
viruses as well as the rapid rate of point mutation, with multiple
amino acids at virtually every position (entropy .2.0) except at
a single region in HA that has remained remarkably conserved
despite the extreme sequence modification of every other nonamer
of the protein. The PB1-F2, NS1 and NS2, and to a lesser extent
M2, also showed a history of high variability. In contrast, the
polymerase proteins (PB2, PB1, and PA), as well as the NP and
M1, contained many historically highly conserved regions (entropy
,1.0). The overall gradual increase in entropy over the three
decades in many of the protein sequences, most apparent in the
highly conserved sequences, is an indication of the continuing
genetic evolution of the viruses as well as improved screening of
sequence variants. However, these changes do not distort the
overall pattern of highly conserved and highly variable sequences.
H5N1 protein entropy patterns of the 1997 to 2006 isolates
from humans (1,055 sequences) and birds (4,361) were grossly
similar and reflect the high mutational variability in amino acid
composition of proteins of even a single subtype influenza A virus
(Figure 3). Of the eleven known influenza A proteins, only the
short PB1-F2 protein, the product of an alternative ORF of the
PB1RNAsegment[73]showednotabledifferenceswhencomparing
the diversity profiles of the two groups. There is evidence that PB1-
F2 is involved in the apoptosis of host immune cells, increased viral
virulence in a mouse model, and destruction of alveolar macro-
phages [74], and the limited diversity of this protein in human
isolatesmayhaverelevancetoH5N1virulenceand pathogenicity.In
the context of the remaining proteins, the similarity of human and
avianH5N1entropypatternsisconsistentwiththeobservationsthat,
to date, all human H5N1 isolates represent avian to human
transmission from isolated clusters of avian infection. Moreover,
detailed analyses of mutations associated with human-to-human
transmission have shown that all human H5N1 virus isolates have
a predominant avian footprint [75]
Entropy of the protein sequences of each of the three circulating
human viruses isolated between 1918 and 2006 (H1N1, 3,850
sequences; H3N2, 17,092; and H1N2, 414 [including 9 sequences
before 1997]) reflect different patterns of sequence evolution
(Figure 4). The complex protein sequence diversity pattern of the
human H1N1 reflects its mutational evolution from its avian
characteristics at the time of human transmission in 1918 to
a sequence characteristic of human H1N1, with the greatest
evolutionary diversity in the HA, NA, PB1-F2, NS1 and NS2, and
to a lesser extent M2, similar to the diversity of the viruses in the
avian host. There subsequently was further evolution of the
Table 2. Influenza A virus protein sequences from virus
isolates before 1997.
......................................................................
Protein Human H1N1 Human H3N2 Other Avian
a Total
1977–1986 1987–1996
PB2 98 337 200 133 768
PB1 106 342 200 134 782
PB1-F2 81 301 181 95 658
PA 96 334 190 135 755
HA 266 1,071 326 252 1,915
NP 133 544 220 153 1,050
NA 142 443 242 145 972
M1 122 398 264 163 947
M2 106 389 258 130 883
NS1 123 373 240 198 934
NS2 111 361 222 173 867
Total 1,384 4,893 2,543 1,711 10,531
aOther avian subtypes of influenza A viruses except H5N1.
doi:10.1371/journal.pone.0001190.t002
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Figure 2. Entropy plots of avian influenza A viruses, excluding H5N1 subtype, for each of three decades: 1977–1986, 1987–1996, 1997–2006
(data as of September 30, 2006).
doi:10.1371/journal.pone.0001190.g002
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1957, H3N2 in 1968, and H1N2 in 1988. The continuing
mutational modification of H1N2 and H3N2 have resulted in
entropy patterns distinctive of the human transmitted influenza A
viruses with a large number of amino acid sequence patterns that
differ from those of the avian to avian counterpart. In contrast, the
most recent H1N2 human subtype that appeared in 1988 (www.
cdc.gov/flu/about/h1n2.htm) continues to exhibit limited evolu-
tionary variability with many identical or highly conserved
sequences regions in all of the few (22 to 66) recorded individual
protein sequences (see Table 1). It is likely that the human H1N2
virus evolved from a very limited, perhaps single reassortment of
the HA gene segment in the case of an individual infected with
both of the human transmitted H1N1 and H3N2 viruses.
The nature of the entropy distribution of the conserved
sequences is not demonstrated in these data as entropy is not
a linear function but is defined both by the number of sites and
frequency of variability. A given entropy value can be related to
a high fraction of different amino acids at one site and limited
variability at other amino acid sites, or to limited variability at
a large number of amino acid sites. This absence of a direct
correlation of entropy to the degree of sequence conservation is
seen in the markedly diverse nonamer entropy values (,0.7 to 1.5)
of the collected sequences with 80% conservation (Figure 5). A
more limited range of entropy values can be associated with
sequence conservation of 90–100%.
We concluded that the PB2, PB1, PA, NP, and M1 proteins of all
recorded influenza A viruses, both avian and human, contain
sequencesoflowvariabilityandhighconservationdespitedifferences
in evolutionary pathway, subtypes, and host species. These
sequences with a history and predicted future of low variability are
prime targets for epitope-based T-cell vaccine formulations.
Amino acid composition of the highly conserved
sequences
A total of 55 peptide sequences, ranging from 9 to 58 amino acids
in length, and containing a total of 965 amino acids, ,21% of the
total proteome (Table 3), were completely conserved in 80%
to100% of the human and avian type A viruses recorded in the
past decade (Figure 6, Table S1). Twenty-six (26) were present in
90% to100% of the viruses. The majority of the conserved
sequences were in the nonstructural (NS) proteins. PB2 was the
most conserved with 23 sequences, comprising 50% of the protein,
conserved in 80% to 100% of the documented viruses (Table 3).
PB1 was also highly conserved (11 sequences, 36%) and the PA,
NP, and M1 proteins contained significant fractions (16% to 27%)
of conserved sequences. HA contained one sequence, FGAIAG-
FIE, that was conserved in all type A viruses despite the extreme
variability of all other HA amino acids (see Figure 2). There were
no sequences in the PB1-F2, NA, M2, NS1 or NS2 proteins that
were completely conserved in at least 80% of the viruses.
Figure 3. Entropy plots of the sequence alignments of recorded H5N1 viruses isolated from avian and human hosts (data as of September 30,
2006).
doi:10.1371/journal.pone.0001190.g003
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had the highest representation of conserved sequences, with almost
all of the 55 sequences present in 95% to 100% of the isolates of
each virus. All but one (22 of 23) of the H1N2 PB2 conserved
sequences were identical in each of the virus isolates. By
comparison, only 62% to 76% of the conserved sequences of the
avian and human H5N1 subgroups, respectively, and only 33% of
the conserved sequences of all other avian subtypes were found in
95–100% of the isolates. The greater proportion of conserved
sequences in the human isolates can be attributed to the more
recent history and limited rate of evolution the influenza viruses
transmitted by humans. This is especially true of the human H1N2
virus, the most recent human influenza A virus.
HLA-restricted T-cell epitopes
The association of conserved sequences and T-cell epitopes was
examined by (a) in silico prediction of HLA-restricted binding
sequences corresponding to supertype alleles by TEPITOPE [24],
NetCTL [25], MULTIPRED [26] and ARB [27] algorithms; and
(b) reported experimental HLA-binding and T-cell assay data.
Most of the peptides representing the conserved sequences (50 of
55) were predicted to contain class I and/or class II binding
sequences (Figure 7). There was no significant difference in the
density of predicted epitopes in the conserved as compared to non-
conserved sequences (data not shown). The detailed listing of
nonamer sequences of the conserved regions and the predicted
supertypes of these specific nonamers in shown as a supplement
(Table S2). For example over 500 HLA class I and over 100 class
II HLA binding sequences of supertype alleles were predicted,
with many of the nonamer sequences predicted to bind to multiple
(2 to 9) individual class I alleles. Similarly, all of the DR binding
predictions were selected as supertypes on the basis of predicted
binding to multiple DR-alleles (individual predictions not shown).
The consistency of class I predictions by the different algorithms
ranged from 31% to 66% in those supertypes (A1, A2, A3, A24,
A26, B7, B44) where more than one computational system was
available. The highest consistency of binding sequences cross-
predicted by more than one system was observed with A2 (57%),
A3 (66%), and DR (56%).
Fourteen (14) of the 55 conserved regions contained a total of 29
reported T-cell epitopes based on T-cell assay and/or HLA-
binding data entered into the Immune Epitope Database and
Analysis Resource (www.immuneepitope.org/) (Figure 8). These
14 experimentally derived sequences included all of the predicted
HLA supertypes of the M1 protein, and 5 of the 11 predicted PB1
supertypes. The majority, 22 of the 29 reported T-cell epitopes,
were present as clusters (hotspots) of 2 or more overlapping or
closely associated reported epitopes; for example, PB1 518-575
contains 5 epitope sequences (9–10 amino acids) between position
537 and 574. Some of the sequences were promiscuous in their
association with multiple supertype alleles, for example, the PA 29-
54 sequence containing the nonamer FMYSDFHFI that was
experimentally shown to bind to at least 5 class I supertype alleles
(A*0201, A*0203, A*0206, A*0202, and A*6802).
Figure 4. Entropy plots of recorded human influenza A subtypes H1N1, H3N2, and H1N2 from 1918–2006 (data as of September 30, 2006).
doi:10.1371/journal.pone.0001190.g004
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1190All but one of these 29 unique influenza A HLA epitopes
reported in the IEDB and located in the conserved sequences are
class I. This HLA distribution differs markedly from the
corresponding total IEDB reported influenza A epitopes repre-
senting the complete viral proteome, which show a much greater
representation, almost 50%, of class II epitopes: 225 class I and 95
class II. Because the conserved sequences represent ,21% of the
total proteome, if there were a random distribution of T-cell
epitopes in the viral proteins, one could expect about 45 class I and
20 class II epitopes in the conserved sequences, as compared to the
observed 28:1. These data are consistent with the conventional
model that T-cell epitopes derived from the PB2, PB1, PA, NP,
and M1 nonstructural proteins that contain the conserved
sequences would be processed primarily in the cytoplasmic
proteosomal class I pathway.
DISCUSSION
The marked variability of influenza A virus surface proteins, the
major targets of the neutralizing antibodies, have posed a serious
obstacle in the development of effective and long-lasting influenza
vaccines. As a possible solution, we have identified virus protein
sequences that are completely conserved in the majority of all
recorded genomic variants that have evolve from avian reservoirs,
both avian and human. The information entropy methodology for
analysis of protein variability was modified to examine sequences
of 9 amino acids or longer, instead of the more common
application to single residues, as a means to relate the conserved
sequences to the immune function of HLA-restricted peptides.
This use of entropy methodology for the identification of highly
conserved protein sequences ushers a new experimental strategy in
Figure 5. Entropy-sequence conservation relationship, plotted from data in this study (see Figure 2–4). The boxed region indicates area whereby
conservation of $90% correlates to entropy of 0.8 or less.
doi:10.1371/journal.pone.0001190.g005
Table 3. The influenza A virus proteins, their length, the
number of conserved sequences, and the combined length of
the conserved sequences of each protein
......................................................................
Protein
Length
(aa)
a
Number of highly
conserved sequences
b
Total length of conserved
sequences (aa)
c
PB2 759 23 379 (50%)
PB1 757 11 271 (36%)
PB1-F2 90 0 0
PA 716 7 111 (16%)
HA 568 1 9 (2%)
NP 498 9 126 (25%)
NA 469 0 0
M1 252 4 69 (27%)
M2 97 0 0
NS1 230 0 0
NS2 121 0 0
Total 4,557 55 965 (21%)
d
aBased on the complete genome sequences of A/Goose/Guangdong/1/96
(H5N1), Taxonomy ID: 93838.
bNumber of high conserved sequences with sequence and nonamer
conservation of $80% in influenza A virus sequences from 1997 to 2006
(human H1N1, human H3N2, human H1N2, human H5N1, avian H5N1, and
other avian subtypes) in each of the 11 proteins.
cThe sum of highly conserved sequences length in each of the 11 proteins. The
numbers in parentheses indicate the percentage of highly conserved
sequences length over the total protein length.
dThe percentage of total highly conserved sequences length over total
influenza A proteome length.
doi:10.1371/journal.pone.0001190.t003
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PLoS ONE | www.plosone.org 8 November 2007 | Issue 11 | e1190Figure 6. Highly conserved sequences of influenza A viruses in human H1N1, H3N2, H1N2, H5N1, avian H5N1, and other avian subtypes circulating
between1997and2006.Aregionintheviralproteomeisconsideredashighlyconservedwhenithasidenticalsequenceconservationofatleast9contiguous
amino acids in 80% or more of the protein sequences of the analyzed dataset. The index of virus colored symbol is as shown at the top of the figure.
doi:10.1371/journal.pone.0001190.g006
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PLoS ONE | www.plosone.org 9 November 2007 | Issue 11 | e1190Figure 7. Highly conserved sequences of influenza A viruses and their predicted HLA class I and II supertype-restricted T-cell epitopes by
NetCTL, ARB, TEPITOPE, and MULTIPRED systems. The color symbols corresponding to the prediction systems are as shown at the top of the figure.
Only conserved sequences containing predicted alleles are shown. NetCTL predicts all of the listed class I supertypes; MULTIPRED predictions cover
A2 and A3; and ARB predicts each of the class I except B8, B27, B39, B58, and B62. Predictions of HLA class II supertypes by MULTIPRED AND TEPITOPE
is described in Materials and Methods.
doi:10.1371/journal.pone.0001190.g007
Influenza A Conservation
PLoS ONE | www.plosone.org 10 November 2007 | Issue 11 | e1190Figure 8. Highly conserved sequences of influenza A viruses and their associated HLA-restricted T-cell epitope based on data obtained from
IEDB (www.immuneepitope.org/). Only sequences with identified sites are included. The first amino acid of each identified allele is shown in bold.
doi:10.1371/journal.pone.0001190.g008
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PLoS ONE | www.plosone.org 11 November 2007 | Issue 11 | e1190the development of vaccines for pathogens with high rates of
mutation. The comprehensive analysis of conserved sequences
may also have other applications to pathogen diagnosis or therapy.
These sequences are known or can be presumed to have critical
roles in viral survival and thus are choice targets for the
development of antiviral agents.
Many reports, particularly with respect to the human
immunodeficiency virus type 1 (HIV-1) have described a strategic
advantage in the use of computational analysis and conserved
sequences for vaccine design [76–83]. Additionally, the analysis of
sequence and immunology databases for the relationship between
amino acid sequences and CTL epitope distributions indicate
a localization of CTL epitopes in conserved regions of proteins [84].
In contrast, the highly variable regions that lacked epitopes showed
evidence of past immune escape with an enrichment of amino acids
that do not serve as C-terminal anchor residues and a paucity of
predicted proteasome processing sites [85–86]. Likewise, the high
genetic variability with continually evolving variants of influenza
viruses favors sequence modifications at all sites that result in
enhanced virus propagation or survival by adaptation to the host cell
immune response. Therefore, a vaccine based upon sequences that
are naturally highly conserved in all influenza A viruses may greatly
restrict the range of possible mutants that could selectively overcome
immune suppression.Sucha vaccine would have significant strategic
advantage provided the sequences have immune function capability,
the designofthe immunogeniscompatiblewiththe requirementsfor
appropriate immune processing and presentation of the protein, and
the epitopes have sufficient HLA-representation to cover the global
distribution of HLA genotypes. It appears that these requirements
can be satisfied given the large number of predicted supertype MHC
binding sequences in the conserved regions of the influenza proteins,
the experimental reports of T-cell epitopes of the conserved
sequences, and our findings of T-cell responses by HLA transgenic
mice to almost all conserved sequences of West Nile virus
(unpublished data).
A question, however, is why influenza A differs from other
pathogens that elicit immune responses to natural infection or
vaccination that prevent repeated infection. It is evident that the
mechanisms involved in the immune response to influenza A virus
infection are in some manner more complex. A discerning report
[87] addresses the ecological and immunological determinants of
influenza evolution in relation to several of the characteristic
features of influenza infection; i.e., the marked replacement of
existing strains during a pandemic caused by antigenic shift, the
short-lived viral sublineages that characterize influenza A infection
and evolution, and the marked seasonality of influenza incidence.
A proposed model [86] to address these characteristic features of
influenza infection and evolution was that the host immune system
responds in a manner that inhibits immediate re-infection but is
short-lived with a time scale of weeks to months and is nonspecific
to intra- and inter-subtypes. This pattern of short-lived, cross-
reactive immunity points to an initial cytotoxic T-lymphocyte
(CTL) response that does not persist. We attribute this to the
extreme variability of the structural proteins of influenza A viruses,
especially that of the HA and NA proteins. Studies of mice and
model pathogens suggest that the initial response of naive CD8
+
T-cells to antigen requires only a brief stimulation with antigen
early in the immune response, in a matter of hours, for the cells to
become activated, divide, and differentiate into short lived effector
cells [88–90]. This initial activation can occur in the absence of T-
cell help, but without the CD4
+ response, the quality of the
cytotoxic response to antigen challenge after priming gradually
decreases and fails to respond effectively to secondary encounters
with antigen. Data of several studies indicate that generation of
long term CD8
+ T-cell immune memory requires the concurrent
function of professional antigen presenting cells for class II antigen
processing and presentation to CD4
+ helper T-cells during the
initial antigen priming period [91–93]. It is likely that the major
sources of T-cell epitopes, both class I and II, early after influenza
infection are those proteins delivered to the immune system by the
virus, including the highly variable structural proteins, HA and
NA. Thus, this initial response, and the memory T-cells elicited by
this response, may lack the highly conserved epitope sequences of
the non-structural proteins that would be synthesized at a later
stage of infection and, as cytoplasmic proteins, function primarily
as endogenous class I epitopes. In this context, it is noteworthy that
of the 29 reported influenza T-cell epitopes found in conserved
sequences, there was only a single class II epitope, further
suggesting that following natural infection, the conserved
sequences elicit primarily cytotoxic T-cell responses.
We suggest that a vaccine composed of conserved influenza A
virus sequences may provide a memory immunity to non-
structural proteins of all viral variants as a means for augmenting
the natural response to the virus structural proteins and to provide
an enhanced and augmented immune response to any newly
emerging avian influenza A pathogen, as well as to the persistence
of mutant forms of human transmitted influenza A. This study
establishes the identity of all the highly conserved sequences of
both human and avian influenza proteomes as the first step in the
selection of these sequences for the synthesis of a supertype,
epitope-based genetic vaccine.
SUPPORTING INFORMATION
Table S1 Highly conserved sequences of influenza A viruses and
their occurrence in each subgroup.
a Highly conserved sequences
refer to sequences with >80% conservation in each of the six
groups that were analyzed.
b The percentage conservation
(rounded down as whole numbers) was calculated as the number
of sequences that are identical to the highly conserved sequences
divided by the total number of sequences in the same position. The
numbers in square brackets indicate the total number of unique
sequences at the considered position, inclusive of the highly
conserved sequences.
c The total number of human H1N1
sequences ranged from 187 to 242.
d The total number of human
H3N2 sequences ranged from 969 to 1141.
e The total number of
human H1N2 sequences ranged from 24 to 40.
f The total number
of human H5N1 sequences ranged from 82 to 106.
g The total
number of avian H5N1 sequences ranged from 217 to 648.
h The
total number of avian influenza A subtypes sequences ranged from
210 to 633.
Found at: doi:10.1371/journal.pone.0001190.s001 (0.26 MB
DOC)
Table S2 Potential HLA-restricted binding sequences in the
highly conserved sequences of influenza A virus that are predicted
by the NetCTL, ARB, TEPITOPE, and MULTIPRED systems.
a Highly conserved sequences of influenza A viruses (Figure 4) and
nonameric binding sequences predicted by NetCTL, ARB,
TEPITOPE, and/or MULTIPRED algorithms. The numbers in
parentheses indicate the number of nonameric binding sequences
in a highly conserved sequence that was predicted by at least one
algorithm.
b Nonamers that bind to HLA class I were predicted
using NetCTL, ARB, and MULTIPRED. NetCTL 1.2 Server
predicts for T cell epitopes that bind to 12 MHC I supertypes, by
integrating MHC binding, proteasomal C terminal cleavage, and
TAP transport efficiency. MULTIPRED predicts for potential
HLA supertype-restricted nonameric sequences that bind to two
HLA class I (A2 and A3) supertypes. Only sequences that were
Influenza A Conservation
PLoS ONE | www.plosone.org 12 November 2007 | Issue 11 | e1190predicted by both artificial neural network (ANN) and hidden
markov model (HMM) are included. ARB predicts for T-cell
epitopes that bind to 30 MHC class I alleles and 12 class II alleles.
This study focused on class I alleles that are the most common in
each supertype (according to Lund et al., 2004), namely class I
A*0101 in A1 supertype, A*0201 in A2 supertype, A*0301 in A3
supertype, A*2402 in A24 supertype, A*2601 in A26 supertype,
B*0702 in B7 supertype, B*4402 and B*4403 in B44 supertype.
Only sequences, 9aa for class I that were predicted to bind to these
common alleles are listed. Nonamers that were predicted to bind
in any one of the three systems are listed.
c Nonamers that bind to
HLA class II were predicted using TEPITOPE and MULTI-
PRED. TEPITOPE predicts for T cell epitopes that bind to 25
MHC II alleles. Only promiscuous nonameric sequences that were
predicted to bind to at least 5 alleles by TEPITOPE system were
listed and indicated as ‘‘DR’’. MULTIPRED predicts for potential
HLA supertype-restricted nonameric sequences that bind to 8
HLA DRB1 alleles. Only sequences that were predicted by both
artificial neural network (ANN) and hidden markov model (HMM)
are included. Nonamers that were predicted to bind in any one of
the two systems are listed.
Found at: doi:10.1371/journal.pone.0001190.s002 (0.55 MB
DOC)
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